You are here

Article info

Article menu

Download PDFPDF

XML
Clinical/translational cancer immunotherapy
Short report
Checkpoint inhibitor-related renal vasculitis and use of rituximab

Authors

  • Omar Mamlouk Division of Internal Medicine, Section of Nephrology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Jamie S Lin Division of Internal Medicine, Section of Nephrology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Maen Abdelrahim Institute of Academic Medicine and Weill Cornell Medical College, Houston Methodist Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Amanda S Tchakarov Department of Pathology and Laboratory Medicine, University of Texas Health Science Center McGovern Medical School, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • William F Glass Department of Pathology and Laboratory Medicine, University of Texas Health Science Center McGovern Medical School, Houston, Texas, USA PubMed articlesGoogle scholar articles
  • Umut Selamet Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA PubMed articlesGoogle scholar articles
  • Maryam Buni Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States PubMed articlesGoogle scholar articles
  • Noha Abdel-Wahab Department of General Internal Medicine, Section of Rheumatology and Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States Department Rheumatology and Rehabilitation, Assiut University Hospitals, Assiut, Egypt PubMed articlesGoogle scholar articles
  • Ala Abudayyeh Division of Internal Medicine, Section of Nephrology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Ala Abudayyeh; aabudayyeh{at}mdanderson.org
View Full Text

Citation

Mamlouk O, Lin JS, Abdelrahim M, et al
Checkpoint inhibitor-related renal vasculitis and use of rituximab
Journal for ImmunoTherapy of Cancer 2020;8:e000750. doi: 10.1136/jitc-2020-000750

Publication history

  • Accepted June 9, 2020
  • First published July 22, 2020.
Online issue publication 
July 22, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.